Candriam S.C.A. Inhibrx, Inc. Transaction History

Candriam S.C.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$14.5 - $38.0 $290,000 - $760,000	-20,000 Reduced 12.9%	135,069 $5.13 Million
Q3 2023 Nov 13, 2023	SELL	$15.75 - $26.31 $504,000 - $841,920	-32,000 Reduced 17.11%	155,069 $2.85 Million
Q4 2022 Feb 13, 2023	SELL	$20.18 - $33.33 $2.02 Million - $3.33 Million	-100,000 Reduced 34.83%	187,069 $4.61 Million
Q3 2022 Nov 10, 2022	SELL	$11.58 - $24.73 $752,700 - $1.61 Million	-65,000 Reduced 18.46%	287,069 $5.15 Million
Q2 2022 Aug 03, 2022	BUY	$8.52 - $25.26 $721,064 - $2.14 Million	84,632 Added 31.65%	352,069 $4 Million
Q1 2022 May 13, 2022	SELL	$19.89 - $43.18 $2.15 Million - $4.66 Million	-107,889 Reduced 28.75%	267,437 $5.96 Million
Q4 2021 Feb 10, 2022	BUY	$26.75 - $46.02 $10 Million - $17.3 Million	375,326 New	375,326 $16.4 Million

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $580M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.